Clinical trials: Elderly Infection
Infections, Meningococcal
Study to Evaluate GlaxoSmithKline (GSK) Biologicals' MenC-TT and Hib-MenC-TT or Meningitec™ in Healthy Toddlers
The purpose of this booster vaccination study is to evaluate the persistence and immune memory induced by a three-dose primary vaccination course with GSK Biologicals' MenC-TT (Neisseria meningitidis group C…
- Trial name
- NCT00135564
- Testing
- MenC-TT, Hib-MenC-TT
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Pandemic Influenza Disease
Safety, Tolerability and Immunogenicity of Two Doses of Adjuvanted Monovalent Influenza Vaccine Administered to Healthy Adult and Elderly Subjects
The present study, phase III, randomized, controlled, observer-blind, multicenter study, will evaluate safety, tolerability and immunogenicity of two doses of an adjuvanted monovalent influenza vaccine compared with an adjuvanted…
- Trial name
- NCT00841763
- Testing
- Trivalent influenza virus vaccine (TIV), Adjuvanted monovalent influenza virus vaccine (aH5N1), Adjuvanted trivalent influenza virus vaccine (aTIV)
- Where
- 2 sites in Finland, Germany
- Volunteers
- 3,647 people, healthy volunteers welcome
- Sponsor
- Novartis
COVID-19
A Global Phase III Clinical Trial of Recombinant COVID- 19 Vaccine (Sf9 Cells)
This Phase III study is a global multicenter, randomized, double-blind,placebo controlled clinical trial to evaluate the efficacy, safety, and immunogenicity of therecombinant COVID-19 vaccine (Sf9 cells) in 40,000 participants…
- Trial name
- NCT04904471
- Testing
- Recombinant COVID-19 vaccine (Sf9 cells)
- Where
- 24 sites in Indonesia, Kenya and 3 more
- Volunteers
- 39,663 people, healthy volunteers welcome
- Sponsor
- WestVac Biopharma Co., Ltd.
Hepatitis B
Comparison of Adjuvanted Hepatitis B Vaccine to Double Dose of Engerix™-B in Pre- /Haemodialysis Patients Aged ≥15 Years
Comparison of adjuvanted hepatitis B vaccine to double dose of Engerix™-B in pre- /haemodialysis patients aged ≥15 years
- Trial name
- NCT00383227
- Testing
- Hepatitis B adjuvanted vaccine
- Volunteers
- 165 people
- Sponsor
- GlaxoSmithKline
Influenza
Safety and Immunogenicity of MF59C.1 Adjuvanted Trivalent Subunit Influenza Vaccine in Elderly Subjects
The present phase III study aims to evaluate the safety and immunogenicity of MF59-adjuvanted subunit seasonal influenza vaccine and to evaluate the consistency in the manufacturing process of three consecutive lots of…
- Trial name
- NCT01162122
- Testing
- MF59 adjuvanted trivalent subunit influenza vaccine (aTIV), Non-adjuvanted trivalent subunit influenza vaccine (TIV)
- Where
- 38 sites in United States, Colombia and 2 more
- Volunteers
- 7,109 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Coronavirus
Recombinant New Coronavirus Vaccine (CHO Cells) to Prevent SARS-CoV-2 Phase I Clinical Trial (≥60 Years Old)
Popular topic: Phase I clinical trial of recombinant new coronavirus vaccine (CHO cell) (≥60 years old) Research purpose: Main purpose: To evaluate the safety and tolerability of different doses of recombinant new coronavirus…
- Trial name
- NCT04550351
- Testing
- Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cell) low-dose group, Biological/Vaccine: Recombinant new coronavirus vaccine (CHO cells) high-dose group
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
HPV Infections, Cervical Cancer Stage IIa
Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine
To access the immune persistence of Chinese women aged 9-45 years after receiving quadrivalent HPV vaccine with the immunization schedule of 0, 2 and 6 months.
- Conditions
- HPV Infections, Cervical Cancer Stage IIa, Vaginal Cancer, Genital Wart
- Trial name
- NCT05371353
- Where
- 2 sites in China
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Shanghai Bovax Biotechnology Co., Ltd.
Influenza, Human
Clinical Trial of Quadrivalent Influenza Virus Split Vaccine in Population Aged 3-8 Years
To evaluate the safety and immunogenicity of quadrivalent influenza virus split vaccine in healthy population aged 3-8 years following different immunization procedures.
- Trial name
- NCT05138705
- Testing
- Quadrivalent Influenza Virus Split Vaccine
- Where
- China
- Volunteers
- 380 people, healthy volunteers welcome
- Sponsor
- Shanghai Institute Of Biological Products
Hepatitis B
Immuno & Safety Study of GSK Biologicals' Thio or Preservative Free Hepatitis B Vaccine in Subjects Aged 11-15 Yrs
To evaluate the persistence of antibodies against hepatitis B at 30, 42, 54 and 66 months after the first dose of the hepatitis B primary vaccination course.
- Trial name
- NCT00343915
- Testing
- Engerix™-B (thiomersal-free) 20µg, 10 μg Engerix™-B (preservative-free)
- Where
- 4 sites in Australia, Belgium and 1 more
- Volunteers
- 267 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COVID-19
Immunogenicity and Safety Study of Recombinant Two-Component COVID-19 Vaccine (CHO Cell)(ReCOV)
This is a multicenter, randomized, observer-blinded, active-controlled Phase II study to evaluate the immunogenicity, safety and reactogenicity of the low dose (20μg) and high dose (40μg) of ReCOV, when administered as a booster…
- Trial name
- NCT05323435
- Testing
- Recombinant two-component COVID-19 vaccine (CHO cell), COVID-19 Vaccine (Vero Cell), Inactivated
- Where
- United Arab Emirates
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Jiangsu Rec-Biotechnology Co., Ltd.
COVID-19
Omicron BA.4/5-Delta COVID-19 Vaccine Phase I Clinical Trial
The purpose of this study is to evaluate the safety of Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells) after vaccination in people aged 18 and over.
- Trial name
- NCT06043388
- Testing
- Omicron BA.4/5-Delta strain recombinant novel coronavirus protein vaccine (CHO cells)
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Yellow Fever
Phase 3 Single Arm, Open Study on vYF in Adults
The purpose of this study is to assess the safety and immunogenicity of vYF in adults aged 18 years and over in Japan. Study details include: The study duration will be up to approximately 1 month.
- Trial name
- NCT07222059
- Testing
- Yellow fever vaccine (live)
- Where
- 4 sites in Japan
- Volunteers
- 254 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Chikungunya Virus Infection
A Phase 2 Clinical Trial of VLA1553 in Healthy Children Aged 1 to 11 Years
This is a multicenter, prospective, randomized, observer-blinded, three arm, phase 2 clinical trial evaluating the full dose formulation of VLA1553, half dose formulation of VLA1553 and control.
- Trial name
- NCT06106581
- Testing
- VLA1553 full dose, VLA1553 half dose, Control
- Where
- 3 sites in Dominican Republic, Honduras
- Volunteers
- 304 people, healthy volunteers welcome
- Sponsor
- Valneva Austria GmbH
Influenza
Safety and Immunogenicity of a Cell Culture-derived Influenza Vaccine in Healthy Adults and Elderly
The present study aims to evaluate the safety and immunogenicity of the new influenza subunit vaccine produced in Madin Darby Canine Kidney (MDCK) cells in healthy adult and elderly subjects.
- Trial name
- NCT00492063
- Testing
- Cell culture-derived trivalent subunit influenza vaccine (cTIV), Egg-derived trivalent subunit influenza vaccine (TIV)
- Where
- 5 sites in Poland
- Volunteers
- 2,654 people, healthy volunteers welcome
- Sponsor
- Novartis Vaccines
Respiratory Syncytial Virus Infections
Phase 1 Study of BLB-201 Vaccine in Healthy Young and Older Adults
This Phase 1 trial is an open-label trial to evaluate the safety, tolerability and immunogenicity of a single dose (10^7.5 PFU) of intranasal BLB-201 (a recombinant parainfluenza virus type 5) administered as a single dose in 15…
- Trial name
- NCT05281263
- Testing
- CPI-RSV-F Vaccine (BLB-201)
- Where
- 2 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Blue Lake Biotechnology Inc.
Prevention of Meningococcal Infection
Persistence of Immune Response After Vaccination With MCC
Persistence of Immune response after vaccination with MCC
- Trial name
- NCT00310687
- Testing
- BLOOD DRAW
- Where
- United Kingdom
- Volunteers
- 1,244 people, healthy volunteers welcome
- Sponsor
- Novartis
Diphtheria, Tetanus
The Transparent Safety Study of the 5 in 1 (DTwP-rHepB-Hib) Combination Vaccine Produced by the Indian Serine Institute in Children of Viet Nam Healthy From 6 to 12 Weeks of Age in a 3-dose Regimen, the Interval Between Doses is 4 Weeks
The objective of this study is to evaluate safety and tolerability of Diphtheria, Tetanus, Pertussis, Hepatitis B and Haemophilus influenzae type b Conjugate Vaccine Adsorbed in Vietnamese infants aged 6-12 weeks.
- Conditions
- Diphtheria, Tetanus, Pertussis, Hepatitis B
- Trial name
- NCT03931239
- Testing
- Study subjects will be vaccinated with 3 (three) vaccine doses. The first vaccine will be administered intramuscularly starting at 6-12 weeks of age followed by two doses at four-week interval
- Where
- Vietnam
- Volunteers
- 222 people, healthy volunteers welcome
- Sponsor
- Vabiotech
Prevention of Infection Disease Caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)
A Study of TAK-019 in Healthy Japanese Adults (COVID-19)
TAK-019 is a vaccine in development to protect people against Covid-19. The main aims of the study are to learn if TAK-019 can protect people from Covid-19 and to check for side effects from TAK-019.
- Trial name
- NCT04712110
- Testing
- TAK-019
- Where
- 2 sites in Japan
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Takeda
Tuberculosis
Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 on Healthy People Aged 18-65(III-healthy)
The investigators recruit about 1800 cases participants who has signed ICF,then do some physical examinations for these people, including ecg, X-ray, HIV,blood pressure, specific gamma-interferon detection ,collection of medical…
- Trial name
- NCT02795260
- Testing
- Bacillus Calmette - Guerin
- Volunteers
- 1,802 people, healthy volunteers welcome
- Sponsor
- Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
COVID-19
Phase II Clinical Trial of Recombinant COVID-19 Variant Vaccine (Sf9 Cell)
A single-center, randomized, double-blind, controlled clinical trial to evaluate the safety and immunogenicity of booster vaccination of Recombinant COVID-19 variant vaccine (Sf9 cell) in healthy people aged 18 years and older…
- Trial name
- NCT05770180
- Testing
- Recombinant COVID-19 variant vaccine (Sf9 cell), Recombinant COVID-19 vaccine (CHO cell), Recombinant COVID-19 vaccine (Sf9 cell)
- Where
- China
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- WestVac Biopharma Co., Ltd.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.